Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

25%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Detailed Status

Completed2

Enrolling by invitation1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

completed250%

enrolling_by_invitation125%

recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

enrolling_by_invitationphase_1

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742

recruitingphase_2

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

NCT06343298

completedphase_1

Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

NCT05247528

completedphase_1

MANP in Hypertension and Metabolic Syndrome

NCT03781739

Clinical Trials (4)

Showing 4 of 4 trials

NCT05279742Phase 1

Enhancing the Natriuretic Peptide System in HFpEF

Enrolling By Invitation

NCT06343298Phase 2

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Recruiting

NCT05247528Phase 1

Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

Completed

NCT03781739Phase 1

MANP in Hypertension and Metabolic Syndrome

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4